Successful use of rasagiline in combination with two antidepressants

A case report

Narpinder Kaur, Rohit Madan, Ashish Sharma

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Parkinson's disease is the second most common neurodegenerative disorder, affecting 1 to 2 percent of people older than 60 years. Recent reviews show that depression is a common and potentially debilitating aspect of Parkinson's disease, affecting 40 to 50 percent of patients. Depression in Parkinson's disease is demonstrably different from ordinary major depression in terms of gender ratio, age, symptom profile, comorbidity, and chronicity. Pharmacotherapy for depression in Parkinson's disease entails special concerns related to side effects and drug-drug interactions. Rasagiline is a novel, potent, and irreversible monoamine oxidase type B (MAO-B) inhibitor that has recently been approved by the Food and Drug Administration for treatment of Parkinson's disease. Current rasagiline labeling advises the avoidance of coadministration of rasagiline and antidepressants, which is a challenge in itself for patients with co-morbid depression. We present a case of a 58-year-old woman who failed most of the pharmacologic treatments for Parkinson's disease, including deep brain stimulation, and was recently prescribed rasagiline with good response. She also met the Diagnostic and Statistical Manual, Fourth Edition, Text Revision criteria of major depressive disorder, which was treated with venlafaxine and bupropion. To our knowledge, this is first clinical case report of successful use of a combination of antidepressants and rasagiline in a patient with Parkinson's disease.

Original languageEnglish (US)
Pages (from-to)39-41
Number of pages3
JournalInnovations in Clinical Neuroscience
Volume9
Issue number11-12
StatePublished - Dec 1 2012

Fingerprint

Antidepressive Agents
Parkinson Disease
Depression
Bupropion
Deep Brain Stimulation
Monoamine Oxidase Inhibitors
Major Depressive Disorder
United States Food and Drug Administration
rasagiline
Drug-Related Side Effects and Adverse Reactions
Drug Interactions
Neurodegenerative Diseases
Comorbidity
Drug Therapy
Therapeutics

Keywords

  • Bupropion
  • Depression
  • Parkinson's disease
  • Rasagiline
  • Venlafaxine

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Successful use of rasagiline in combination with two antidepressants : A case report. / Kaur, Narpinder; Madan, Rohit; Sharma, Ashish.

In: Innovations in Clinical Neuroscience, Vol. 9, No. 11-12, 01.12.2012, p. 39-41.

Research output: Contribution to journalArticle

@article{0df05493cf8747b4ae8db724329090b1,
title = "Successful use of rasagiline in combination with two antidepressants: A case report",
abstract = "Parkinson's disease is the second most common neurodegenerative disorder, affecting 1 to 2 percent of people older than 60 years. Recent reviews show that depression is a common and potentially debilitating aspect of Parkinson's disease, affecting 40 to 50 percent of patients. Depression in Parkinson's disease is demonstrably different from ordinary major depression in terms of gender ratio, age, symptom profile, comorbidity, and chronicity. Pharmacotherapy for depression in Parkinson's disease entails special concerns related to side effects and drug-drug interactions. Rasagiline is a novel, potent, and irreversible monoamine oxidase type B (MAO-B) inhibitor that has recently been approved by the Food and Drug Administration for treatment of Parkinson's disease. Current rasagiline labeling advises the avoidance of coadministration of rasagiline and antidepressants, which is a challenge in itself for patients with co-morbid depression. We present a case of a 58-year-old woman who failed most of the pharmacologic treatments for Parkinson's disease, including deep brain stimulation, and was recently prescribed rasagiline with good response. She also met the Diagnostic and Statistical Manual, Fourth Edition, Text Revision criteria of major depressive disorder, which was treated with venlafaxine and bupropion. To our knowledge, this is first clinical case report of successful use of a combination of antidepressants and rasagiline in a patient with Parkinson's disease.",
keywords = "Bupropion, Depression, Parkinson's disease, Rasagiline, Venlafaxine",
author = "Narpinder Kaur and Rohit Madan and Ashish Sharma",
year = "2012",
month = "12",
day = "1",
language = "English (US)",
volume = "9",
pages = "39--41",
journal = "Innovations in Clinical Neuroscience",
issn = "2158-8333",
publisher = "Matrix Medical Communications",
number = "11-12",

}

TY - JOUR

T1 - Successful use of rasagiline in combination with two antidepressants

T2 - A case report

AU - Kaur, Narpinder

AU - Madan, Rohit

AU - Sharma, Ashish

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Parkinson's disease is the second most common neurodegenerative disorder, affecting 1 to 2 percent of people older than 60 years. Recent reviews show that depression is a common and potentially debilitating aspect of Parkinson's disease, affecting 40 to 50 percent of patients. Depression in Parkinson's disease is demonstrably different from ordinary major depression in terms of gender ratio, age, symptom profile, comorbidity, and chronicity. Pharmacotherapy for depression in Parkinson's disease entails special concerns related to side effects and drug-drug interactions. Rasagiline is a novel, potent, and irreversible monoamine oxidase type B (MAO-B) inhibitor that has recently been approved by the Food and Drug Administration for treatment of Parkinson's disease. Current rasagiline labeling advises the avoidance of coadministration of rasagiline and antidepressants, which is a challenge in itself for patients with co-morbid depression. We present a case of a 58-year-old woman who failed most of the pharmacologic treatments for Parkinson's disease, including deep brain stimulation, and was recently prescribed rasagiline with good response. She also met the Diagnostic and Statistical Manual, Fourth Edition, Text Revision criteria of major depressive disorder, which was treated with venlafaxine and bupropion. To our knowledge, this is first clinical case report of successful use of a combination of antidepressants and rasagiline in a patient with Parkinson's disease.

AB - Parkinson's disease is the second most common neurodegenerative disorder, affecting 1 to 2 percent of people older than 60 years. Recent reviews show that depression is a common and potentially debilitating aspect of Parkinson's disease, affecting 40 to 50 percent of patients. Depression in Parkinson's disease is demonstrably different from ordinary major depression in terms of gender ratio, age, symptom profile, comorbidity, and chronicity. Pharmacotherapy for depression in Parkinson's disease entails special concerns related to side effects and drug-drug interactions. Rasagiline is a novel, potent, and irreversible monoamine oxidase type B (MAO-B) inhibitor that has recently been approved by the Food and Drug Administration for treatment of Parkinson's disease. Current rasagiline labeling advises the avoidance of coadministration of rasagiline and antidepressants, which is a challenge in itself for patients with co-morbid depression. We present a case of a 58-year-old woman who failed most of the pharmacologic treatments for Parkinson's disease, including deep brain stimulation, and was recently prescribed rasagiline with good response. She also met the Diagnostic and Statistical Manual, Fourth Edition, Text Revision criteria of major depressive disorder, which was treated with venlafaxine and bupropion. To our knowledge, this is first clinical case report of successful use of a combination of antidepressants and rasagiline in a patient with Parkinson's disease.

KW - Bupropion

KW - Depression

KW - Parkinson's disease

KW - Rasagiline

KW - Venlafaxine

UR - http://www.scopus.com/inward/record.url?scp=84874312040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874312040&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 39

EP - 41

JO - Innovations in Clinical Neuroscience

JF - Innovations in Clinical Neuroscience

SN - 2158-8333

IS - 11-12

ER -